Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02640508 | Eribulin and Lenvatinib in Advanced Solid Tumors | completed | Phase 2 | 29 | Virginia G. KaklamaniOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT04742959 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 203 |
| TransThera Sciences (Nanjing), Inc.INDUSTRY |
| 1 |
| Apr 26, 2024 |
| clinicaltrials |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | completed | Phase 2 | 730 | ExelixisINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05160051 | 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer | completed | Phase 2 | 158 | University Hospital, EssenOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | completed | Phase 2 | 290 | InventisBio Co., LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03890731 | A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed | completed | Phase 2 | 6 | BayerINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT02034981 | Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1(AcSé) | completed | Phase 2 | 246 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03274661 | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | completed | Phase 2 | 52 | Baptist Health South FloridaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03253679 | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01827384 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | completed | Phase 2 | 208 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT04346381 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | completed | Phase 2 | 233 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03834948 | AO-176 in Multiple Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02506517 | A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene | completed | Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | completed | Phase 1 / Phase 2 | 113 | Revolution Medicines, Inc.INDUSTRY | 2 | Jun 26, 2023 | clinicaltrials |
| NCT02797977 | A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects | completed | Phase 1 / Phase 2 | 153 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 22, 2023 | clinicaltrials |
| NCT04122625 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143(SMARTPLUS-106) | completed | Phase 1 / Phase 2 | 46 | Debiopharm International SAINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT05898451 | Effect of Refnot on Immunity in Cancer Patients(R-2) | completed | Phase 2 | 55 | Refnot-Pharm LtdINDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT01752920 | Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | completed | Phase 1 / Phase 2 | 119 | Basilea PharmaceuticaINDUSTRY | 2 | Jun 5, 2023 | clinicaltrials |
| NCT02426892 | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03577704 | The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.(HLX07Ib/II) | completed | Phase 1 / Phase 2 | 56 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809336 | Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors | completed | Phase 2 / Phase 3 | 172 | Beijing Friendship HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 235 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 5, 2023 | clinicaltrials |
| NCT03616834 | Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy | completed | Phase 2 | 39 | Effector TherapeuticsINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | completed | Phase 2 | 345 | PharmaMarINDUSTRY | 9 | Mar 2, 2023 | clinicaltrials |
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 2 | 248 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04592484 | A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Codiak BioSciencesINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT04481009 | A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Dec 12, 2022 | clinicaltrials |
| NCT02762981 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | completed | Phase 1 / Phase 2 | 85 | Corcept TherapeuticsINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT02593786 | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors(CheckMate 077) | completed | Phase 1 / Phase 2 | 58 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02910726 | A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers | completed | Phase 2 / Phase 3 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT03085914 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | completed | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2024source: clinicaltrials